

THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in any doubt as to what action you should take, you are recommended to seek your own financial advice from your stockbroker or other independent adviser authorised under the Financial Services and Markets Act 2000.

If you have sold or transferred all of your shares in BATM Advanced Communications Ltd., please forward this document, together with the accompanying documents, as soon as possible either to the purchaser or transferee or to the person who arranged the sale or transfer so they can pass these documents to the person who now holds the shares.

Please note that this document sets out different voting processes for securities traded on the London Stock Exchange and for securities traded on the Tel-Aviv Stock Exchange. You must follow the correct process applicable to the securities you hold. If you hold multiple types of securities, you must follow a different process for each portion of your holding (see note 4 below in the Notes to the Notice of Annual General Meeting for further information regarding the process).

BATM ADVANCED COMMUNICATIONS LTD.

Notice of Annual General Meeting

of 10 December 2025

Chairman's letter

5 November 2025

Dear Shareholder,

Annual General Meeting

I enclose the notice of the Annual General Meeting (“AGM” or “**the Meeting**”) of BATM Advanced Communications Ltd. (or “**the Company**”), which is to be held at the Company's offices at 4 Ha'harash Street, Nave Ne'eman Industrial Area, P.O.B. 7318, 4524075 Hod Hasharon, Israel on 10 December 2025 at 12.00 p.m. Israel-time (10.00 a.m. UK-time) (the “**Notice**”).

In order to enable shareholder engagement and participation for those unable to physically attend the Meeting, shareholders will be able to access the Meeting via videoconference.

PLEASE NOTE, shareholders will not be able to vote at the Meeting via the videoconference. Shareholders attending the Meeting via videoconference are therefore strongly encouraged to submit their vote in advance of the AGM, in accordance with the Notes to the Notice of General Meeting set out below. To register to attend the AGM via videoconference, please email yair.livneh@batm.com, stating your full name, at your earliest opportunity and no later than 7.30 p.m. Israel-time (5.30 p.m. UK-time) on 3 December 2025.

Background to the Meeting

In addition to those matters which are dealt with annually, at the AGM this year the Company is asking its members to approve a specific transaction with a related party, namely a director and significant shareholder, Dr. Zvi Marom. Dr. Marom did not participate in the Board discussions nor the Board vote concerning this transaction. In addition, Dr. Marom has undertaken not to vote on the resolution concerning the transaction.

I would like to draw your attention to Note A in this Notice that gives further information on the terms and financials relating to the transaction.

Recommendation

The Board believes that all the resolutions to be considered at the AGM are in the best interests of the Company and are most likely to promote the success of the Company for the benefit of its members as a whole, and recommends that you vote in favour of all the proposed resolutions.

Yours sincerely,

Dr. Gideon Chitayat
Chairman

Notice is hereby given that the Annual General Meeting ("AGM" or the "Meeting") of BATM Advanced Communications Ltd. ("BATM" or the "Company") will be held at the Company's offices at 4 Ha'harash Street, Nave Ne'eman Industrial Area, building E, 12th floor, Hod Hasharon, Israel on 10 December 2025 at 12.00 p.m. Israel-time (10.00 a.m. UK-time).

The purpose of the AGM is to receive and discuss the Company's audited annual accounts for the year ended 31 December 2024 and the directors' report thereon and to consider and, if thought fit, pass the resolutions detailed below, including the sale of A.M.S 2000 Trading Impex SRL.

RESOLUTIONS

I. Annual Report, Accounts and Re-appointment of Auditors

1. To receive the Company's audited annual accounts for the financial year ended 31 December 2024 together with the directors' report and the auditor's report on those accounts.
2. To approve the report of the Company's Remuneration Committee for the financial year ended 31 December 2024 together with the auditor's report on the auditable part of the remuneration report.
3. To re-appoint the auditors of the Company (Brightman Almagor Zohar & Co., a Firm in the Deloitte Global Network) as external auditors for the 2025 financial year and to authorise the Board of Directors to fix the auditor's remuneration for such period.

II. Sale of Diagnostics Distributor

4. To approve the sale of A.M.S 2000 Trading Impex SRL, a subsidiary of the Company that distributes diagnostic laboratory equipment in Romania, by Sunstring Ltd (of which the Company has 100% indirect ownership), to a related party of the Company, Dr. Zvi Marom, in exchange for the transfer to Sunstring Ltd of Dr. Marom's entire holding in the Company (96,794,500 ordinary shares of the Company, which represent c. 22.2% of the Company's shares in issue and admitted to trading) in accordance with the terms of the sale agreement, which are set out in Note A below.

III. Election and Re-election of Directors

5. To re-elect Dr. Gideon Chitayat to the Board of Directors of the Company until the next Annual General Meeting of the Company (Note B).
6. To re-elect Mr. Moti Nagar to the Board of Directors of the Company until the next Annual General Meeting of the Company (Note B).
7. To re-elect Dr. Avigdor Shafferman to the Board of Directors of the Company until the next Annual General Meeting of the Company (Note B).
8. To re-elect Dr. Shmuel Ben Zvi to the Board of Directors of the Company until the next Annual General Meeting of the Company (Note B).
9. To elect Mr. Leor Miles to the Board of Directors of the Company until the next Annual General Meeting of the Company (Note B).
10. To elect Mr. Gil Sharon to the Board of Directors of the Company until the next Annual General Meeting of the Company (Note B).

11. To elect Mrs. Ayala Hakim to the Board of Directors of the Company as an "external director" (as defined in the Israeli Companies Law) for a term of three years (Note B).

IV. Disapplication of pre-emption rights

12. That the directors will be generally authorised and empowered to allot equity securities pursuant to the authority conferred by article 10B of the Company's articles of association as if article 10A (existing shareholders' right of pre-emption) did not apply to the allotment provided that this power shall:

- 12.1 refer to the allotment of equity securities or sale of treasury shares up to such number of equity securities that equal 10% of the issued and allotted share capital of the Company;
- 12.2 refer to the allotment of equity securities or sale of treasury shares (otherwise than under paragraph 12.1 above) up to a nominal amount equal to 20% of any allotment of equity securities or sale of treasury shares from time to time under paragraph 12.1 above, such authority to be used only for the purposes of making a follow-on offer that the Board of the Company determines to be of a kind contemplated by paragraph 3 of Section 2B of the Statement of Principles on Disapplying Pre-emption Rights most recently published by the Pre-emption Group prior to the date of this notice;
- 12.3 be limited to the allotment of equity securities or sale of treasury shares up to such number of equity securities that equal 10% of the issued and allotted share capital of the Company, such authority to be used only for the purposes of financing (or refinancing, if the authority is to be used within 12 months after the original transaction) a transaction that the Board of the Company determines to be either an acquisition or a specified capital investment of a kind contemplated by the Statement of Principles on Disapplying Pre-emption Rights most recently published by the Pre-emption Group prior to the date of this notice;
- 12.4 be limited to the allotment of equity securities or sale of treasury shares (otherwise than under paragraph 12.3 above) up to a nominal amount equal to 20% of any allotment of equity securities or sale of treasury shares from time to time under paragraph 12.3 above, such authority to be used only for the purposes of making a follow-on offer that the Board of the Company determines to be of a kind contemplated by paragraph 3 of Section 2B of the Statement of Principles on Disapplying Pre-emption Rights most recently published by the Pre-emption Group prior to the date of this notice; and
- 12.5 such disapplication to expire on the earlier of 31 March 2027 (unless renewed, varied or revoked by the Company prior to or on that date), or on the date of the next Annual General Meeting of the Company save, however, that the Company may, before such expiry make an offer or agreement that would or might require equity securities to be allotted after such expiry and the Directors may allot equity securities in pursuance of any such offer or agreement notwithstanding that the power conferred by this resolution has expired.

(see Note C)

Dated: 5 November 2025

Resolutions 1-3 and 5-10 are being proposed as ordinary resolutions, and resolutions 4 and 11-12 are being proposed as special resolutions.

In accordance with Israeli law, resolution 11 requires the special majority set forth in section 239 of the Israeli Companies Law for the appointment of external directors. Please see Note B for an explanation of such requirements.

Explanatory Notes to the Resolutions

Note A:

This resolution seeks shareholder approval for the sale of A.M.S 2000 Trading Impex SRL ("AMS"), by Sunstring Ltd, to a related party of the Company, Dr. Zvi Marom, in exchange for the transfer to Sunstring Ltd of Dr. Marom's entire holding in the Company pursuant to a sale agreement (the "Sale Agreement") signed with Dr. Marom on 5 October 2025 and announced by the Company on 6 October 2025. The completion of the transaction is subject to independent shareholder approval (Dr. Marom undertook not to vote on the resolution) and all other legal and regulatory requirements.

AMS is a wholly owned indirect subsidiary of the Company that distributes diagnostic laboratory equipment in Romania. Dr. Marom owns 96,794,500 ordinary shares in the Company, representing c. 22.2% of the Company's issued share capital as at the date of this Notice.

The transaction values AMS, excluding the laboratories and excess cash retained by the Company, at £17.6m (c. \$23.7m). This valuation is based on the closing price of the Company's ordinary shares on the Main Market of the London Stock Exchange on 3 October 2025, being the trading day prior to the signing of the Sale Agreement and the prevailing GBP-USD exchange rate. Dr. Marom's offer exceeded the value of a competing offer that the Company received for the disposal of AMS. As noted below, the directors, excluding Dr. Marom, have consulted Shore Capital in relation to the terms of the transaction, and consider them to be fair and reasonable as far as shareholders are concerned.

Background to the transaction

Since June 2023, the Company has been executing on a clear strategy for the business to focus on its core strengths of networks, cybersecurity and diagnostics, and to dispose of all non-core assets. The Company is prioritising its higher-margin activities that are in substantial, high-growth markets and where it can leverage its decades of experience of delivering highly innovative solutions. By disposing of its non-core assets, the Company will be able to provide greater resources and focus to its identified core strengths to drive growth in these activities where the Board believes greater opportunities exist to maximise shareholder value.

AMS, which was established in 1997 and acquired by the Company in 2007, is an authorised importer and distributor in the Romanian market of diagnostic laboratory equipment, including reagents and laboratory supplies, from leading international brands. It also has two laboratories that perform genetic, microbiological, physio-chemical and environmental analyses, which will be taken out of AMS prior to the sale. The Company will continue to own and operate the two laboratories, which it will seek to sell as part of its ongoing strategy to dispose of non-core assets.

AMS has approximately 100 employees across several offices, a warehouse and the laboratories in Romania. The proposed sale will reduce the operational complexity of the Company and enable savings in central corporate costs.

For the year ended 31 December 2024, AMS generated revenue of \$34.2m, a gross margin of 28% and net profit of \$2.7m prior to any allocation of central corporate costs. This includes the contribution from the laboratories, which accounted for c. 11% of AMS revenue in 2024.

For the Company's reporting purposes, AMS was incorporated within the BATM Diagnostics division as the business had begun to distribute the Company's proprietary diagnostic products alongside third-party products. However, its activities are non-core to the Company's high-margin, high-growth and high-technology focus. Accordingly, the Board believes it is in the best interests of the Company and its shareholders to dispose of AMS for the reasons outlined above.

Terms of the transaction

Sunstring Ltd, a wholly-owned subsidiary of the Company, has agreed pursuant to the Sale Agreement to sell AMS to Dr. Marom in exchange for the transfer to Sunstring Ltd of Dr. Marom's entire shareholding in the Company (the "Consideration Shares"). The agreed consideration is according to the average closing price of the Company's shares on the London Stock Exchange in the 30 trading days prior to the signing of the Sale Agreement (£0.163325 per share). AMS is being sold on a "cash free, debt free" basis, subject to retention in AMS of normative working capital. Prior to completion of the transaction, AMS will transfer the shares it currently owns in AMS Laborator Genetic srl and the business of Jebel laboratories to the Company at no consideration.

Completion of the transaction is subject to the following conditions:

1. Approval of the transaction by the general meetings of the shareholders of the Company and of AMS.
2. No creditor of the Company objects to the transaction within the time limit set in the Israeli regulations; or, if creditors do object, a court approval for the transaction is obtained.
3. Certain customers and suppliers confirm their agreement to the change of ownership in AMS.

If either party withdraws from the transaction following satisfaction of the conditions, liquidated damages of US\$2,000,000 are payable by the defaulting party to the non-defaulting party.

Sunstring Ltd, the Company and AMS have given warranties and indemnities customary for a transaction of this type in respect of the sale of AMS. Dr. Marom has given title and capacity warranties in respect of the Consideration Shares.

The Sale Agreement contains typical pre-completion covenants. At completion, Dr. Marom will resign from all of his roles with the Company.

The Sale Agreement contains a mutual non-compete covenant and a restriction on each party using the other party's intellectual property rights relating to the business of AMS or the Company (respectively), in each case for a period of 3 years.

Resultant holdings, total voting rights and options and restricted share units (“RSUs”)

Under the terms of the Sale Agreement, following completion of the transaction, the Consideration Shares will be held by Sunstring Ltd, of which the Company has 100% indirect ownership (or with another company, at the Company's discretion). In accordance with Israeli law, as the Consideration Shares are held by a subsidiary of the Company, they would not have any voting rights (section 309(b) of the Israeli Companies Law) and therefore, on completion of the transaction, the total number of ordinary shares with voting rights in the Company is expected to reduce to 339,887,169 ordinary shares. This would be the figure used by shareholders as the denominator for the calculations by which they would determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

As at 4 November 2025, being the latest date prior to publication of this Notice, the Company has outstanding RSUs and options over, in aggregate, 30,152,072 Ordinary Shares – comprising 29,959,566 options and 192,515 RSUs – representing, in aggregate, c. 6.9% of the issued share capital. With effect from completion of the Sale Agreement, assuming no other changes in the Company's issued share capital, the RSUs and options will, in aggregate, represent c. 6.9% of the issued share capital and, excluding the Consideration Shares (which will be held by a subsidiary of the Group on a non-voting basis), c. 8.9% of the voting rights.

Rule 9 waiver

The completion of the transaction, as outlined above, would result in Lombard Odier holding over 30% of the voting rights of the Company. As a company incorporated in Israel, the Company is not bound by the City Code on Takeovers and Mergers (the “UK Takeover Code”). However, as per the Company's articles of association (the “Articles”), the Company has chosen to voluntarily adopt the principles of the UK Takeover Code, but, in accordance with the Articles, the Board of Directors has full authority to determine its application. Accordingly, the Board has resolved that Lombard Odier holding over 30% of the voting rights of the Company to be a permitted acquisition under the terms of the Articles and thus there would not be an obligation under the section of the Articles that has adopted Rule 9 of the UK Takeover Code for Lombard Odier to make a mandatory offer for the Company.

Related party transaction

By reason of Dr. Marom being a non-executive director and significant shareholder of the Company, the transaction would constitute a related party transaction under UK Listing Rule 8.2.1R. The Independent Directors of the Company, having been so advised by Shore Capital, acting in their capacity as sponsor to the Company, consider the terms of the transaction to be fair and reasonable so far as the shareholders of the Company are concerned. The Independent Directors also took into account a valuation report by an independent consultancy that was commissioned by the Board, with the value of the Consideration Shares being in line with the report's estimated value for AMS. Dr. Marom did not participate in any of the Board deliberations concerning this transaction and the transaction has been approved by the Company's Audit Committee. In addition, and as noted above, the proposed transaction with Dr. Marom represents the best offer that the Company received for the disposal of AMS.

As a related party, Dr. Marom has undertaken not to vote on resolution 4 (being the sale of AMS).

Following completion, Dr. Marom will cease to be a shareholder of the Company and will resign from all of his roles with the Company.

Shore Capital has given and not withdrawn its written consent to the inclusion of the reference to its name in the form and context in which it is included.

Note B:

1. Dr. Chitayat is the Chairman of the Board of the Company. He has been a Board member since 2010 and the Chairman since 2015. The Board considers Dr. Chitayat as independent in character and judgement. His knowledge of the business and the understanding of its various components, which is built on his experience, combined with his independence of mind, enables a critical review of strategy and operations. In addition, his vast business experience, expertise and knowledge of directing large business organisations within Israel is a valuable resource for the Board and the Company as a whole. Dr. Chitayat has informed the Company that he intends to step down as Chairman and as a Board member at the end of 2025, following election by the Board of one of the Board members as the new Chairman (in accordance with Israeli law) and an orderly transition process. The Board believes that Dr. Chitayat remaining as Chairman until that time is in the best interests of the Company and its shareholders as a whole.
2. Mr. Nagar has been the Chief Executive Officer of the Company since 1 January 2023. Prior to that, he was the CFO and a director of the Company. He joined the Company in 2014. During his time at the Company, Mr. Nagar has been instrumental in driving the business' development, including leading several M&A transactions, the Company's IPO on TASE and, since his appointment as CEO, renewing the Company's strategy and executing on the updated strategy, including defining the Company's core businesses, focusing the Company's efforts and resources according to the newly defined business priorities, restructuring the Company (including disposals and pursuing M&A activity), and building a management team. Prior to joining the Company, Mr. Nagar held several senior positions at Deloitte, which he joined in 2005. As a Senior Manager, Mr. Nagar was responsible for handling the accounts of leading corporate clients in Israel and overseas, with companies traded on the LSE, NASDAQ and TASE as well as private businesses operating in a range of sectors. Mr. Nagar graduated in Business Management and Accounting and qualified as an Israeli Certified Public Accountant (CPA, Israel) in 2008. He also holds an MBA in Financial Management from Tel Aviv University.
3. Dr. Avigdor Shafferman was appointed as a non-executive director on 13 April 2022. Dr. Shafferman had an established career at the Israel Institute for Biological Research, a leading governmental applied research institute specialising in the fields of biology, medicinal chemistry and environmental sciences, where he worked for almost 40 years. Most recently, from 1995 until his retirement in 2013, he was Director General of the organisation. Other roles have included serving as a visiting professor in the University of California, San Diego at the biology department as well as a visiting senior research scientist at various leading research institutions in the US in various medical areas, including vaccines. The Company has classified Dr. Shafferman as an Independent Director (as defined under Israeli law), and he serves as a member of the Audit Committee, Remuneration Committee, Nomination Committee and Responsible Business Committee.
4. Dr. Shmuel (Muli) Ben Zvi was appointed as a director on 19 December 2024. He was elected Chairman of the board of Bank Leumi, the largest banking corporation in Israel, in October 2023 for the final year of his nine-year tenure as a director. At Bank Leumi, he was a member of the board's audit, risk management, credit, technology and strategy committees. Dr. Ben Zvi has extensive executive and board experience across multiple industries, including currently being a director of Protalix Biotherapeutics (NYSE

American: PLX) and previously of Sol-Gel Technologies (NASDAQ: SLGL) and VBL Therapeutics (NASDAQ: VBLT). From 2004 to 2014, he held a number of managerial positions at Teva Pharmaceuticals (NASDAQ and TASE: TEVA), including Vice President of Strategy and Vice President of Finance. From 2000 to 2004, Dr. Ben Zvi was the Financial Advisor to the Chief of General Staff of the Israel Defense Forces and Head of the Defense Ministry Budget Department. Dr. Ben Zvi holds a B.A., M.A. and Ph.D. in Economics from Tel Aviv University. He also participated in the Harvard Business School Advanced Management Program and in National Security & Political Science programmes at the National Security College, Israel and Haifa University, Israel. Dr. Ben Zvi performed post-doctoral studies in Economics at the Massachusetts Institute of Technology.

5. Dr. Chitayat, Mr. Nagar, Dr. Shafferman and Dr. Ben Zvi were re-appointed or appointed as directors at the 2024 AGM until the then-next AGM of the Company. The shareholders are requested to re-appoint each of Dr. Chitayat, Mr. Nagar, Dr. Shafferman and Dr. Ben Zvi for an additional term with such term to expire at the next AGM of the Company. Their re-election requires a simple majority, as set out under sections 59 and 85 of the Israeli Companies Law and article 39 of the Company's Articles of Association.

In addition to the re-election of Dr. Chitayat, Mr. Nagar, Dr. Shafferman and Dr. Ben Zvi, the shareholders are requested to elect 3 new directors - Mr. Leor Miles, Mr. Gil Sharon and Mrs. Ayala Hakim.

6. Mr. Leor Miles has been the CFO of BATM since 22 June 2025. Mr. Miles brings over 15 years' experience in financial management for public and private companies operating globally primarily in the technology industry, including serving as VP Finance of the Company from 2015-2021. He re-joined the Company from Kenes Group where, as Group CFO, he oversaw financial operations, including investments, cash management, risk management, insurance, M&A, taxation and financial strategy, for the global operations across 18 locations on four continents. Other experience includes being Director of Finance for Abra Information Technologies Ltd., a TASE-listed provider of IT services and solutions, and its subsidiaries in the US and Israel. He commenced his career as an accountant at PwC, where he performed company audits in accordance with US GAAP and IFRS standards. The shareholders are requested to appoint Mr. Miles to the Board with such appointment term to expire at the next AGM of the Company. His election requires a simple majority, as set out under sections 59 and 85 of the Israeli Companies Law.
7. Mr. Gil Sharon brings over 30 years' experience in the telecommunications industry as a senior executive. He is currently Chairman of IBC, an Israeli fibre optic communications company. Prior to IBC, he was Executive Chairman of Bezeq Group (TASE: BEZQ), the largest telecommunications group in Israel, and Chairman of its subsidiaries: Pelephone, a mobile network operator; Yes, a television and internet service provider; and Bezeq International, a business internet services, international communication, integration and IT solutions company. Other roles have included Chairman, CEO and co-investor of Golan Telecom.
8. Mrs. Ayala Hakim is currently a director of Bank Yahav, which is a retail bank in Israel that was established in 1954. She served as the Chief Information Officer of Mizrahi-Tefahot Bank Ltd., one of Israel's largest financial institutions, and CEO of its technology division since 2013 until 2025. During her tenure, Mrs. Hakim led large-scale digital transformations, enterprise IT strategy – including harnessing and leveraging technology to implement the bank's business strategy and create new business opportunities – and

complex system integrations. Prior to joining Mizrahi-Tefahot Bank, Mrs. Hakim spent over 30 years in leadership roles focusing on technology and IT for the Israeli government.

The shareholders are requested to elect Mrs. Hakim as an "external director" (as defined in the Israeli Companies Law). According to the Israeli Companies Law, the term of office of an external director is three years and the Company is entitled to re-appoint the director for two additional terms of three years each. As the Board has recommended that Mrs. Hakim be appointed as external director, the shareholders are requested to appoint her for a three-year term (in accordance with the Israeli Companies Law). This resolution requires the special majority set forth in section 239 of the Israeli Companies Law for the appointment of external directors.

Under section 239 of the Israeli Companies Law, external directors are appointed by the General Meeting provided one of the following conditions is met: (a) The appointment is supported by a majority of the shareholders participating in the vote at the General Meeting who are not a controlling party and do not have a personal interest in the appointment (except for a personal interest which is not as a result of a relationship with a controlling party), excluding abstaining votes; or (b) the aggregate number of those voting against the proposed resolution did not exceed two per cent of the aggregate voting rights in the company.

Note C:

The proposed resolution is to allow the Company to disapply the pre-emption rights in the Company's articles of association for up to 10% of the allotted and issued share capital of the Company for general purposes, together with a further 20% of the relevant offer for a follow-on offer, and 10% for specified purposes in accordance with the Pre-Emption Group's most recent statement of principles, together with a further 20% of the relevant offer for a follow-on offer. This will expire on 31 March 2027 or, if held earlier, on the Company's next annual general meeting. If passed it will give the directors power, pursuant to the authority to allot equity securities (as defined by section 560 of the United Kingdom Companies Act 2006) and to sell treasury shares for cash without first offering them to existing shareholders in proportion to their existing holdings as the directors otherwise consider necessary. The maximum amount will be such number of shares that represent no more than 24% of the issued and allotted share capital of the Company. This proposed resolution is in line with guidance by the Investment Association, the Pre-Emption Group's Statement of Principles and the template resolutions published by the Pre-Emption Group in 2022. This resolution requires the special majority set forth in the definition of "Special Resolution" in article 1 of the Company's Articles of Association.

Dated: 5 November 2025

By order of the Board
Moti Nagar

Chief Executive Officer

Company number: 52-0042813

Registered office: 4 Ha'harash Street, Nave Ne'eman, PO
Box 7318, Hod Ha'sharon, 4524075 Israel.

Notes to the Notice of Annual General Meeting

1. Only those members registered on the Company's register of members at close of business on 19 November 2025 (the "**Record Date**") shall be entitled to attend and vote at the Meeting.
2. Information regarding the Meeting is available and can be found on the Company's website at www.batm.com.
3. Quorum and adjourned meeting – the quorum shall be two or more shareholders present in person or by proxy. If such quorum is not present within one hour from the time scheduled for the Meeting, the Meeting will be adjourned for one week (to the same day, time and place). Any two members present in person or by proxy at the adjourned meeting, shall be deemed a quorum.
4. Enclosed with this document is (1) a form of proxy for holders of certificated securities admitted to trading on the London Stock Exchange (a "Form of Proxy"), (2) a form of direction for holders of uncertificated securities (i.e. Depositary Interests) representing ordinary shares admitted to trading on the London Stock Exchange (the "Form of Direction"), and (3) a form of proxy for holders of the Company's shares listed on the Tel-Aviv Stock Exchange (a "Form of Proxy to a TASE Member"). Please note that this document sets out different processes for securities admitted to trading on the London Stock Exchange and securities traded on the Tel-Aviv Stock Exchange. You must follow the correct process applicable to the securities you hold. If you hold multiple types of securities, you must follow a different process for each portion of your holdings.
5. **Shareholders holding through the London Stock Exchange** - If you are a member of the Company at the time set out in Note 1 above, you are entitled to appoint a proxy to exercise all or any of your rights at the Meeting. A proxy need not be a member of the Company but must attend the Meeting to represent you. Details of how to appoint your proxy are set out in the notes to the proxy form. **In order to be valid, proxy forms must be lodged at either MUFG Corporate Markets (the Company's registrar), at its address (MUFG Corporate Markets, PXS 1, Central Square, 29 Wellington Street, Leeds LS1 4DL, United Kingdom) or at the registered office of the Company in Israel marked for the attention of the CFO not less than 48 hours prior to the Meeting. A Form of Proxy appears below. Alternatively, you may submit your proxy electronically via the Investor Centre, a free app provided by MUFG Corporate Markets. It allows you to securely manage and monitor your shareholdings in real time, take part in online voting, keep you details up to date and more. The same voting deadline of 48 hours before the time of the Meeting applies. The app is available to download on both the Apple App Store and Google Play, or by scanning the relevant QR code below, or can be accessed via a web browser at: <https://uk.investorcentre.mpms.mufg.com/>. If you need help with voting online, please contact our registrar, MUFG Corporate Markets, by email at shareholderenquiries@cm.mpms.mufg.com, or on 0371 664 0300. Calls are charged at the standard geographic rate and will vary by provider. Calls outside the United Kingdom will**

be charged at the applicable international rate. Lines are open between 9.00 a.m. – 5.30 p.m., Monday to Friday excluding public holidays in England and Wales.



6. In the case of a member which is a corporation, the proxy (or any related document) should be given under its common seal or under the hand of an officer or attorney duly authorised in writing. Any power of attorney or any other authority under which the Form of Proxy is signed (or a duly certified copy of such party or authority) must be included with the Form of Proxy.
7. In the case of joint holders, where more than one of the joint holders purports to appoint a proxy, only the appointment submitted by the most senior holder will be accepted. Seniority is determined by the order in which the names of the joint holders appear in the Company's register of members in respect of the joint holding (the first-named being the most senior).
8. A corporation which is a shareholder can appoint one or more corporate representatives who may exercise, on its behalf, all its powers as a shareholder provided that no more than one corporate representative exercises powers over the same share.
9. To change your proxy instructions, simply submit a new proxy appointment using the methods set out above. Note that the cut-off time for receipt of proxy appointments (see above) also applies in relation to amended instructions. Any amended proxy appointment received after the relevant cut-off time will be disregarded.

If you submit more than one valid proxy appointment, the appointment received last before the latest time for the receipt of proxies will take precedence.

In order to revoke a proxy instruction, you will need to inform the Company by sending a hard copy notice clearly stating your intention to revoke your proxy appointment to MUFG Corporate Markets at the address referred to above. The revocation notice must be received by MUFG Corporate Markets not less than 48 hours prior to the Meeting.

10. A vote withheld is not a vote in law, which means that the vote will not be counted in the calculation of votes for or against the resolution. If you either select the "Discretionary" option or if no voting indication is given, your proxy will vote or abstain from voting at his or her discretion. Your proxy will vote (or abstain from voting) as he or she thinks fit in relation to any other matter that is put before the Meeting.
11. In the case of holders of Depositary Interests representing shares in the Company, a Form of Direction must be completed in order to direct MUFG Corporate Markets Trustees (Nominees) Limited, the Depositary, to vote on the holder's behalf at the Meeting (in person or by proxy) or, if the Meeting is adjourned, at the adjourned meeting. **In order to be effective, a completed and signed Form of Direction (and any power of attorney or other authority under which it is signed) must be delivered to MUFG Corporate**

Markets, PXS 1, Central Square, 29 Wellington Street, Leeds LS1 4DL, United Kingdom by no later than 72 hours before the time fixed for the Meeting or any adjourned meeting. A Form of Direction appears below.

12. If you are a holder of Depositary Interests, your shares are held on your behalf in the name of MUFG Corporate Markets Trustees (Nominees) Limited, who are the registered shareholder. You can tell them how you want the votes in respect of your shares to be cast at the meeting and any adjournment(s) thereof, by utilising the CREST electronic proxy appointment service as per the procedures described in the CREST Manual (available from www.euroclear.com). CREST personal members or other CREST sponsored members, and those CREST members who have appointed a voting service provider(s), should refer to their CREST sponsor or voting service provider(s), who will be able to take the appropriate action on their behalf.

In order for an instruction made using the CREST service to be valid, the appropriate CREST message (a CREST Proxy Instruction) must be properly authenticated in accordance with Euroclear UK & International Limited's specifications and must contain the information required for such instruction, as described in the CREST Manual (available via www.euroclear.com). The message, regardless of whether it constitutes a new instruction or is an amendment to the instruction given previously must, in order to be valid, be transmitted so as to be received by the Company's registrars (ID: RA10) by no later than 72 hours before the time fixed for the Meeting or any adjourned meeting. For this purpose, the time of receipt will be taken to be the time (as determined by the time stamp applied to the message by the CREST Application Host) from which the issuer's agent is able to retrieve the message by enquiry to CREST in the manner prescribed by CREST. After this time, any change of instructions through CREST should be communicated to the Depositary through other means.

CREST members and, where applicable, their CREST sponsors or voting service providers should note that Euroclear UK & International Limited does not make available special procedures in CREST for any particular messages. Normal system timings and limitations will therefore apply in relation to the input of CREST Proxy Instructions. It is the responsibility of the CREST member concerned to take (or, if the CREST member is a CREST personal member or sponsored member or has appointed a voting service provider(s), to procure that his CREST sponsor or voting service provider(s) take(s)) such action as shall be necessary to ensure that a message is transmitted by means of the CREST system by any particular time. In this connection, CREST members and, where applicable, their CREST sponsors or voting service providers are referred, in particular, to those sections of the CREST Manual concerning practical limitations of the CREST system and timings (www.euroclear.com).

The Company may treat as invalid a CREST Proxy Instruction in the circumstances set out in Regulation 35(5)(a) of the Uncertificated Securities Regulations 2001 (as amended).

13. The Depositary will appoint the Chair of the meeting as its proxy to cast its votes. The Chair of the meeting may also vote or abstain from voting as they think fit on any other business (including amendments to resolutions) which may properly come before the meeting. The 'Abstain' option is provided to enable you to abstain from voting on the resolutions. However, it should be noted that an 'Abstain' is not a vote in law and will not be counted in the calculation of the proportion of the votes 'For' and 'Against' a resolution.
14. Depositary interest holders wishing to attend the meeting should contact the Depositary at MUFG Corporate Markets, Central Square, 29 Wellington Street, Leeds, LS1 4DL or by

emailing Nominee.Enquiries@cm.mpms.mufig.com by no later than 72 hours before the time fixed for the Meeting or any adjourned meeting.

15. **Shareholders holding through the TASE** - Shareholders may vote their shares by appointing the TASE Member (bank, broker or other nominee that is admitted as a member of the TASE) through which they hold their shares as “proxies” to vote on their behalf, and they must direct the TASE Member on how to vote their shares. A duly executed Form of Proxy must be received by the TASE Member no later than 10.00 a.m. (Israel-time) on 3 December 2025, in order to be counted in the vote to be held in the Meeting. A shareholder’s returned proxy may be revoked at any time prior to its exercise by giving written notice to the TASE Member of such revocation, sending a duly executed Form of Proxy bearing a later date, no later than 10.00 a.m. (Israel-time) on 3 December 2025, requesting the return of the original Form of Proxy. The vote at the Meeting shall be carried out by the TASE Clearing House. The TASE Member shall direct the TASE Clearing House on how to vote the shares held by it, according to the TASE Clearing House by-laws, and submit to the TASE Clearing House a summary of the final results of all the proxies received by it and which it requests the TASE Clearing House to vote in its name, including the information required in the Form of Proxy regarding personal interests of the shareholders, if they are senior officers in the Company or controlling shareholders in the Company or a foreign institutional client, joint investment fund manager or trust fund, by no later than 2.00 p.m. (Israel-time) on 3 December 2025. A shareholder whose ordinary shares are registered with a TASE Member and are not registered on the Company’s shareholder register is entitled to receive from the TASE Member who holds the ordinary shares on the shareholder’s behalf, by email, for no charge, a link to the text of the Form of Proxy and to the position statements posted on the Israel Securities Authority website unless the shareholder has notified that he or she is not so interested; provided that the notice was provided with respect to a particular securities account prior to the Record Date. Beneficial owners who hold ordinary shares through TASE Members, or the TASE, would ordinarily be able to attend the Meeting by presenting a certificate signed by the TASE Member through which the shares are held, which complies with the Israel Companies Regulations (Proof of Ownership for Voting in General Meetings)-2000 as proof of ownership of the shares, or they may send such certificate to the Company’s registered office prior to the Meeting. However, beneficial owners who hold ordinary shares through TASE Members will not be able to vote at the Meeting in person and will have to follow the voting instructions detailed in this sub-section 15 and in the Form of Proxy.
16. Appointment of a proxy does not preclude you from attending the Meeting and voting in person (except for shareholders whose shares are listed on the TASE, to whom sub-section 15 herein shall apply).
17. The Company will answer at the Meeting any question you submit in advance as detailed above relating to the business being dealt with unless:
 - 17.1 answering the question would interfere unduly with the preparation for the Meeting or involve the disclosure of confidential information;
 - 17.2 the answer has already been given on a website in the form of an answer to a question; or
 - 17.3 it is undesirable in the interest of the Company or the good order of the Meeting that the question be answered.

18. As at 4 November 2025, the Company's issued share capital comprised 441,176,669 ordinary shares of 0.01 NIS each, including 4,495,000 ordinary shares held in treasury. Each ordinary share (other than those held in treasury) carries the right to one vote at a general meeting of the Company and, therefore, the total number of voting rights in the Company as at 4 November 2025 is 436,681,669.
19. If you hold securities traded on the London Stock Exchange and do not have a Form of Proxy or Form of Direction and believe that you should have one, or if you require additional forms, please contact MUFG Corporate Markets via email at shareholderenquiries@cm.mpms.mufg.com or on 0371 664 0300 if calling from the UK (calls are charged at the standard geographic rate and will vary by provider) or +44 (0)371 664 0300 if calling from outside the UK.
20. You may not use any electronic address provided either:
- 20.1 in this notice of Annual General Meeting; or
- 20.2 any related documents (including the Chairman's letter and proxy form)
- to communicate with the Company for any purposes other than those expressly stated.
21. Information concerning the Company may be found on its website at www.batm.com.
22. The following documents will be available for inspection at **the registered office of the Company** from 5 November 2025 until the time of the Meeting and at the Meeting venue itself for at least 15 minutes prior to the Meeting until the end of the Meeting:
- A copy of the current Company's articles of association
 - A copy of the proposed Remuneration Policy

[THIS PAGE IS INTENTIONALLY LEFT BLANK]

Form of Proxy

(for holders of securities listed on the London Stock Exchange)

**For use at the Annual General Meeting
of BATM Advanced Communications Ltd. To be convened
At 12.00 p.m. Israel-time (10.00 a.m. UK-time) on 10 December 2025 at the Company's
offices at 4 Ha'harash Street, Nave Ne'eman Industrial Area, building E, 12th floor, Hod
Hasharon, Israel**

I/We

of

being a member of the Company hereby appoint/ the Chairman of the meeting to act as my/our proxy and to vote for me/us as indicated below with an "X" at the Annual General Meeting of the Company convened for 10 December 2025 at 12.00 p.m. Israel-time (10.00 a.m. UK-time) and at any adjournment.

Date Signed

Please indicate how you wish to vote with an "X" in the appropriate box opposite the resolution. If no specific indication as to voting is given, the proxy will vote or abstain in their own direction as they will on any other matter arising at the meeting.

No.	Resolution	Your vote		
		For	Against	Abstain
1.	To receive the annual accounts and directors' and auditor's reports thereon			
2.	To approve the report of the Remuneration Committee			
3.	To re-appoint the auditors of the Company and authorise the Board of Directors to fix their remuneration			
4.	To approve the sale of AMS to Dr. Marom (related party) in exchange for his entire holdings in the Company (c. 22.2% of the Company's shares in issue and admitted to trading)			
5.	To re-elect Dr. Gideon Chitayat to the Board			
6.	To re-elect Mr. Moti Nagar to the Board			
7.	To re-elect Dr. Avigdor Shafferman to the Board			
8.	To re-elect Dr. Shmuel Ben Zvi to the Board			

No.	Resolution	Your vote		
		For	Against	Abstain
9.	To elect Mr. Leor Miles to the Board			
10.	To elect Mr. Gil Sharon to the Board			
11.	To elect Mrs. Ayala Hakim to the Board as an External Director			
12.	To authorise the directors to allot equity securities as if article 10A of the Company's articles of association did not apply			

Notes:

1. This Form of Proxy to be valid must be completed and signed and must be deposited with MUFG Corporate Markets to its address (at **MUFG Corporate Markets, PXS 1, Central Square, 29 Wellington Street, Leeds LS1 4DL, United Kingdom**) or at the registered office of the Company not less than 48 hours before the time fixed for the meeting.

Alternatively, you may submit your proxy electronically using the Investor Centre service at <https://uk.investorcentre.mpms.mufg.com/>. Shareholders can use this service to vote or appoint a proxy online.
2. In the case of a corporation, this proxy should be under its common seal, or if not so required, under the hand of an officer duly authorised in writing.
3. In the case of joint holders, the signature of any one of them will suffice but the vote of the senior who tenders a vote whether in person or by proxy will be accepted to the exclusion of the votes of the other joint holders and for this purpose, seniority shall be determined by the order in which the names stand on the Company's register of members in respect of the joint holding.
4. Any alteration made in the form of proxy should be initialled.
5. By voting using this Form of Proxy you are declaring that you have no personal interest (as defined in Israeli Companies Law) in the approval of any of the resolutions except a personal interest of which, if applicable, you have specifically informed the Company. In accordance with Israeli Companies Law, a 'personal interest' is deemed to be a personal interest in the engagement contemplated by the resolution, including the interest of certain family relatives and of corporations affiliated to any person having such interest, but excluding a personal interest stemming from the fact of a shareholding in the Company.
6. You are referred to the Notes to the Notice of Annual General Meeting for further information.

Form of Direction

**For use by holders of Depositary Interests representing shares on a one-for-one basis in
BATM Advanced Communications Ltd. ("BATM") in respect of the Annual General
Meeting of BATM to be convened on 10 December 2025 at 12.00 p.m. Israel-time (10.00 a.m.
UK-time) at the Company's offices at 4 Ha'harash Street, Nave Ne'eman Industrial Area,
building E, 12th floor, Hod Hasharon, Israel**

I/We

of

being a holder of Depositary Interests representing shares in BATM hereby direct MUFG Corporate Markets Trustees (Nominees) Limited, the Depositary, to vote for me/us and on my/our behalf in person or by proxy at the Annual General Meeting of BATM to be held on the above date (and at any adjournment thereof) as directed by an "X" in the appropriate box opposite the resolution. **If no indication is given, you will be deemed as instructing the Depositary to abstain from voting.**

No.	Resolution	Your vote		
		For	Against	Abstain
1.	To receive the annual accounts and directors' and auditor's reports thereon			
2.	To approve the report of the Remuneration Committee			
3.	To re-appoint the auditors of the Company and authorise the Board of Directors to fix their remuneration			
4.	To approve the sale of AMS to Dr. Marom (related party) in exchange for his entire holdings in the Company (c. 22.2% of the Company's shares in issue and admitted to trading)			
5.	To re-elect Dr. Gideon Chitayat to the Board			
6.	To re-elect Mr. Moti Nagar to the Board			
7.	To re-elect Dr. Avigdor Shafferman to the Board			
8.	To re-elect Dr. Shmuel Ben Zvi to the Board			
9.	To elect Mr. Leor Miles to the Board			
10.	To elect Mr. Gil Sharon to the Board			
11.	To elect Mrs. Ayala Hakim to the Board as an External Director			

No.	Resolution	Your vote		
		For	Against	Abstain
12.	To authorise the directors to allot equity securities as if article 10A of the Company's articles of association did not apply			

Signature:

Date:

Notes:

1. To be effective, this Form of Direction and the power of attorney or other authority (if any) under which it is signed, or a notarised or otherwise certified copy of such power of attorney, must be deposited at MUFG Corporate Markets, PXS 1, Central Square, 29 Wellington Street, Leeds LS1 4DL, United Kingdom not later than 72 business hours before the time appointed for holding the meeting.
2. Any alterations made to this Form of Direction should be initialled.
3. In the case of a corporation, this Form of Direction should be given under its common seal or under the hand of an officer or attorney duly authorised in writing.
4. Please indicate how you wish your votes to be cast by placing "X" in the boxes provided. On receipt of this form duly signed, you will be deemed to have authorised MUFG Corporate Markets to vote as per your instructions.
5. The Depositary will appoint the Chairman of the meeting as its proxy to cast your votes. The Chairman may also vote or abstain from voting as he or she thinks fit on any other resolution (including amendments to resolutions) that may properly come before the meeting.
6. If a Depositary Interest holder wishes to attend the Annual General Meeting, they should notify MUFG Corporate Markets (the Depositary) accordingly who will issue a Letter of Representation to the Depositary Interest holder giving them authorisation to attend the Annual General Meeting. If any Depositary Interest holder attends the Annual General Meeting without a Letter of Representation, they will only be allowed to enter the Annual General Meeting as a guest. Requests for a Letter of Representation should be made to the Depositary at MUFG Corporate Markets, PXS 1, Central Square, 29 Wellington Street, Leeds LS1 4DL, United Kingdom or by email to Nominee.Enquiries@cm.mpms.mufg.com no later than 72 business hours prior to the meeting or any adjourned meeting.
7. By voting using this Form of Direction you are declaring that you have no personal interest (as defined in Israeli Companies Law) in the approval of any of the resolutions except a personal interest of which, if applicable, you have specifically informed the Company. In accordance with Israeli Companies Law, a 'personal interest' is deemed to be a personal interest in the engagement contemplated by the resolution, including the interest of certain family relatives and of corporations affiliated to any person having such interest, but excluding a personal interest stemming from the fact of a shareholding in the Company.
8. Depositary Interest Holders may also vote through the CREST Proxy Voting Service in accordance with the procedures set out in the CREST manual.
9. You are referred to the Notes to the Notice of Annual General Meeting for further information.

Form of Proxy

For Holders of Shares Listed on the Tel-Aviv Stock Exchange

For use at the Annual General Meeting

of BATM Advanced Communications Ltd, Israeli company no. 520042813,
to be convened at 12.00 p.m. Israel-time (10.00 a.m. UK-time) on 10 December 2025 at the
Company's offices at 4 Ha'harash Street, Nave Ne'eman Industrial Area, building E, 12th
floor, Hod Hasharon, Israel

I/We

ID / company number

being a holder of share(s) of the Company listed on the Tel-Aviv Stock Exchange and entitled to attend and vote hereby appoint (the "TASE Member") to vote on my behalf in person or by proxy as indicated below with an "X" at the Annual General Meeting of the Company convened for 10 December 2025 at 12.00 p.m. Israel-time (10.00 a.m. UK-time) and at any adjournment thereof.

Date Signed

Please indicate how you wish to vote with an "X" in the appropriate box opposite the resolution. If no specific indication as to voting is given, the TASE Member (or his proxy) will vote or abstain in their own direction as they will on any other matter arising at the meeting.

No.	Resolution	Your vote		
		For	Against	Abstain
1.	To receive the annual accounts and directors' and auditor's reports thereon			
2.	To approve the report of the Remuneration Committee			
3.	To re-appoint the auditors of the Company and authorise the Board of Directors to fix their remuneration			
4.	To approve the sale of AMS to Dr. Marom (related party) in exchange for his entire holdings in the Company (c. 22.2% of the Company's shares in issue and admitted to trading)			
5.	To re-elect Dr. Gideon Chitayat to the Board			
6.	To re-elect Mr. Moti Nagar to the Board			
7.	To re-elect Dr. Avigdor Shafferman to the Board			
8.	To re-elect Dr. Shmuel Ben Zvi to the Board			

No.	Resolution	Your vote		
		For	Against	Abstain
9.	To elect Mr. Leor Miles to the Board			
10.	To elect Mr. Gil Sharon to the Board			
11.	To elect Mrs. Ayala Hakim to the Board as an External Director			
12.	To authorise the directors to allot equity securities as if article 10A of the Company's articles of association did not apply			

Notes:

1. For this Form of Proxy to be valid, the broker, bank or other nominee company through which the shareholder holds their shares must receive, by no later than 10.00 a.m. (Israel-time) on 3 December 2025, a legible PDF scan of the duly completed and signed Form of Proxy.
2. In the case of a corporation, this proxy should be under its common seal, or if not so required, under the hand of an officer duly authorised in writing.
3. In the case of joint holders, the signature of any one of them will suffice but the vote of the senior who tenders a vote whether in person or by proxy will be accepted to the exclusion of the votes of the other joint holders and, for this purpose, seniority shall be determined by the order in which the names stand on the Company's register of members in respect of the joint holding.
4. The TASE Member or their proxy will appoint the Chairman of the meeting as their proxy to cast your votes. The Chairman may also vote or abstain from voting as he or she thinks fit on any other resolution (including amendments to resolutions) that may properly come before the meeting.
5. Any alteration made in the Form of Proxy should be initialled.
6. By voting using this Form of Proxy you are declaring that you have no personal interest (as defined in Israeli Companies Law) in the approval of any of the resolutions except a personal interest of which, if applicable, you have specifically informed the Company. In accordance with Israeli Companies Law, a 'personal interest' is deemed to be a personal interest in the engagement contemplated by the resolution, including the interest of certain family relatives and of corporations affiliated to any person having such interest, but excluding a personal interest stemming from the fact of a shareholding in the Company.
7. You are referred to the Notes to the Notice of Annual General Meeting for further information.